{
  "id": 10278017,
  "title": "StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit",
  "url": "https://urgent.news/2026/09/27/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in",
  "topic": "world",
  "section": "World",
  "published": "2026-09-27T19:05:38.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/translational-medicine/stockwatch-nektar-shares-flat-as-90m-jury-verdict-less-than-sought-in-lilly-suit/"
  },
  "original_language": "en",
  "account": "Nektar Therapeutics' shares remained flat on Friday after a $90 million jury verdict in a legal dispute with Eli Lilly. The San Francisco biotech had sought $1 billion in damages, but the $90 million award represents only a 4.4% increase in stock price. Nektar's shares rose early in trading but quickly declined to below $57.00 by mid-morning. Despite the setback, the company sees the verdict as a non-dilutive capital addition to its balance sheet. The rezpeg drug, a first-in-class therapeutic targeting the CD25 sub-receptor in the interleukin-2 receptor complex, showed promising results in atopic dermatitis trials, with dose-dependent improvements in the Eczema Area and Severity Index (EASI) and a decrease in itching for many patients. Nektar is now advancing rezpeg into pivotal studies in atopic dermatitis and alopecia areata.",
  "summary": "This past week, Nektar Therapeutics (Nasdaq: NKTR) offered an uncommon example of victory in court translating into defeat on Wall Street. Nektar’s shares finished Friday flat, dipping 4% from $59.38 to $57.06 despite a jury siding with the San Francisco biotech over Eli Lilly (NYSE: LLY) in a three-year-old legal dispute over the pharma giant’s terminating a collaboration agreement to co-develop…",
  "key_points": [
    "Nektar shares flat after $90M jury verdict in Lilly suit",
    "4.4% increase in stock price from $90M award",
    "Rezpeg drug shows promise in atopic dermatitis trials"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}